UA76934C2
(en)
*
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
ATE297219T1
(de)
|
1997-02-12 |
2005-06-15 |
Chugai Pharmaceutical Co Ltd |
Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
|
EP1059533A4
(en)
*
|
1998-02-25 |
2005-02-09 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR THE IMMUNOLOGICAL DETECTION OF ANTI-HM1.24 ANTIBODY
|
WO2001077362A1
(fr)
*
|
2000-04-06 |
2001-10-18 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage immunologique d'anticorps anti hm1 . 24
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
ES2869895T3
(es)
*
|
2001-03-09 |
2021-10-26 |
Chugai Pharmaceutical Co Ltd |
Método de purificación de proteínas
|
AU2002315857B2
(en)
*
|
2001-06-22 |
2007-07-26 |
Kaisha, Chugai Seiyaku Kabushiki |
Cell proliferation inhibitors containing anti-glypican 3 antibody
|
US20080219974A1
(en)
*
|
2002-03-01 |
2008-09-11 |
Bernett Matthew J |
Optimized antibodies that target hm1.24
|
US7732149B2
(en)
|
2002-04-26 |
2010-06-08 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of screening agonistic antibodies
|
NZ545720A
(en)
*
|
2004-07-09 |
2010-01-29 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican 3 antibody
|
MX2007004593A
(es)
*
|
2004-10-26 |
2007-06-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-glipican 3 que tiene cadena de azucar modificada.
|
US8329186B2
(en)
*
|
2004-12-20 |
2012-12-11 |
Isu Abxis Co., Ltd |
Treatment of inflammation using BST2 inhibitor
|
US20080299128A1
(en)
*
|
2006-06-20 |
2008-12-04 |
Myung Kim |
Effect of Bst2 on inflammation
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
AU2006318449B2
(en)
|
2005-11-23 |
2012-07-05 |
Acceleron Pharma Inc. |
Activin-actRIIa antagonists and uses for promoting bone growth
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
US11046784B2
(en)
*
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
DK2009101T3
(en)
*
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
WO2008036688A2
(en)
*
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
CA2677007A1
(en)
|
2007-02-01 |
2008-08-07 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for treating or preventing breast cancer
|
TWI782836B
(zh)
|
2007-02-02 |
2022-11-01 |
美商艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
TWI667038B
(zh)
|
2007-02-09 |
2019-08-01 |
美商艾瑟勒朗法瑪公司 |
包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途
|
WO2008150494A1
(en)
|
2007-05-30 |
2008-12-11 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
RS52305B
(en)
|
2007-07-16 |
2012-12-31 |
Genentech Inc. |
ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
|
US7960343B2
(en)
|
2007-09-18 |
2011-06-14 |
Acceleron Pharma Inc. |
Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
|
MY163473A
(en)
*
|
2007-09-26 |
2017-09-15 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
SI2202245T1
(sl)
|
2007-09-26 |
2016-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
|
MY148637A
(en)
|
2007-09-28 |
2013-05-15 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican-3 antibody having improved kinetics in plasma
|
ES2450755T3
(es)
|
2007-10-19 |
2014-03-25 |
Genentech, Inc. |
Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco
|
DK2236604T3
(en)
*
|
2007-12-05 |
2016-10-03 |
Chugai Pharmaceutical Co Ltd |
The anti-NR10 antibody and use thereof
|
ES2587392T3
(es)
|
2008-01-31 |
2016-10-24 |
Genentech, Inc. |
Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
|
CN107488228A
(zh)
|
2008-04-11 |
2017-12-19 |
中外制药株式会社 |
与多个分子的抗原反复结合的抗原结合分子
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
SI3750552T1
(sl)
|
2008-08-14 |
2023-10-30 |
Acceleron Pharma Inc. |
GDF pasti
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
CN107267520A
(zh)
|
2009-06-12 |
2017-10-20 |
阿塞勒隆制药公司 |
截短的actriib‑fc融合蛋白
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
US8710016B2
(en)
|
2009-11-17 |
2014-04-29 |
Acceleron Pharma, Inc. |
ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
ES2603559T5
(es)
*
|
2010-02-08 |
2021-02-22 |
Regeneron Pharma |
Cadena ligera común de ratón
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
CN103298832A
(zh)
|
2010-11-08 |
2013-09-11 |
阿塞勒隆制药公司 |
Actriia结合剂及其用途
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
RU2658504C9
(ru)
|
2010-11-30 |
2018-08-21 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
|
KR20230005405A
(ko)
|
2011-02-25 |
2023-01-09 |
추가이 세이야쿠 가부시키가이샤 |
FcγRIIb 특이적 Fc 항체
|
SI3572517T1
(sl)
|
2011-08-05 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Humanizirana miš z univerzalno lahko verigo
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
US8765385B2
(en)
*
|
2011-10-27 |
2014-07-01 |
Ravindra Kumar |
Method of detection of neutralizing anti-actriib antibodies
|
EP3348140B1
(en)
|
2012-03-16 |
2020-12-30 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
SG10201700360VA
(en)
|
2012-03-16 |
2017-03-30 |
Regeneron Pharma |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
SG10201607727PA
(en)
|
2012-03-16 |
2016-11-29 |
Regeneron Pharma |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
CA2890217C
(en)
|
2012-11-02 |
2021-07-20 |
Yifu FANG |
Activin-actrii antagonists and uses for treating bone and other disorders
|
BR112016006197B1
(pt)
|
2013-09-27 |
2023-04-11 |
Chugai Seiyaku Kabushiki Kaisha |
Método para produzir um anticorpo biespecífico de polipeptídeos
|
CA2942697A1
(en)
|
2014-03-21 |
2015-09-24 |
Lynn Macdonald |
Non-human animals that make single domain binding proteins
|
WO2015192111A1
(en)
|
2014-06-13 |
2015-12-17 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ulcers
|
EP3262071B8
(en)
|
2014-09-23 |
2022-05-18 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
WO2016098356A1
(en)
|
2014-12-19 |
2016-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
EP3240804A4
(en)
|
2014-12-19 |
2019-01-09 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
|
EP3816179A3
(en)
|
2015-02-05 |
2021-08-04 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant comprising a modified fcrn-binding domain
|
KR20180095740A
(ko)
|
2015-02-27 |
2018-08-27 |
추가이 세이야쿠 가부시키가이샤 |
Il-6 관련 질환 치료용 조성물
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
|
AU2017230091B2
(en)
|
2016-03-10 |
2022-04-07 |
Acceleron Pharma Inc. |
Activin type 2 receptor binding proteins and uses thereof
|
EP3431102A4
(en)
|
2016-03-14 |
2019-09-25 |
Chugai Seiyaku Kabushiki Kaisha |
THERAPEUTIC MEDICINE INDUCING CELLULAR INJURY FOR USE IN THE TREATMENT OF CANCER
|
EP4371570A2
(en)
|
2016-06-08 |
2024-05-22 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
CN107619443B
(zh)
*
|
2016-07-14 |
2020-08-14 |
深圳宾德生物技术有限公司 |
抗人和鼠cd317的单克隆抗体及其制备方法和应用
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
JP7185884B2
(ja)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|